Introduction
============

Trypanosomiasis and leishmaniasis are among the major debilitating and devastating tropical diseases that are targets for the World Health Organization's special program Research and Training in Tropical Diseases (TDR) ([@b54-dti-2-2007-129]) and most recently the Drugs for Neglected Diseases initiative (DNDi, [www.dndi.org](www.dndi.org)). These diseases are caused by the parasites of the genus *Trypanosoma* and *Leishmania*. The present review focuses on the major human diseases caused by trypanosomal and leishmanial infections and the potential targets for designing chemotherapeutic agents against these diseases with special emphasis on trypanothione reductase. [Table 1](#t1-dti-2-2007-129){ref-type="table"} gives an outline of the major human trypanosomiasis and leishmaniasis with their global annual disease burdens (as of 1999) in terms of disability adjusted life years (DALY).

Suramine (1) and pentamidine (2) are useful drugs for treating Human African Trypanosomiasis (HAT) during early infection, but being highly charged, cannot cross the blood brain barrier and are of no use for late stage infection with involvement of central nervous system (CNS) with either *Trypanosoma brucei gambiense* or *T. b. rhodesiense*. Melarsoprol (3), a trivalent arsenical, or tryparsamide (4) is then used. Difluoromethylornithine (DFMO, 5) is effective in treatment of HAT, but is not very effective against rhodesiense sleeping sickness where large doses must be used, resulting in significant side-effects, including bone marrow suppression ([@b72-dti-2-2007-129]; [@b74-dti-2-2007-129]). Nifurtimox (6), a nitrofuran derivative, is the best drug currently available for treating Chagas disease but is still considered investigational. It is thought to kill trypanosomes selectively through futile cycling by the formation of hydrogen peroxide and toxic oxygen species ([@b23-dti-2-2007-129]; [@b65-dti-2-2007-129]; [@b24-dti-2-2007-129] and [@b25-dti-2-2007-129], [@b26-dti-2-2007-129]; [@b74-dti-2-2007-129]). Benznidazole (**7**) is of equivalent effectiveness and is used in South America in the acute stage. Both drugs must be given for several months and are associated with severe side effects ([@b74-dti-2-2007-129]). Recently, the present and future prospects of chemotherapy of HAT, in addition to the possible mode of action and the mechanism of resistance of the current chemotherapeutic agents have been reviewed ([@b36-dti-2-2007-129]).

Pentavalent antimonials e.g. pentostam (8) is the recommended treatment for visceral leishmaniasis but are toxic and developed resistance ([@b20-dti-2-2007-129]; [@b48-dti-2-2007-129]). Relapse of disease or only partial response is more common in Kenya, the Sudan, and India than in Mediterranean or Latin American kala azar, where a second or longer course of treatment is often needed.

Overall, the demand for chemotherapeutic agents for the treatment of Chagas disease, sleeping sickness and kala azar is desperate. Those needing treatment are mainly in impoverished rural and urban communities with poor housing and limited access to medical attention, and in countries where basic healthcare infrastructures have yet to be developed. Approved chemotherapies that are available were developed in the first half of the last century (suramine, pentamidine, arsenicals and antimonials); some would fail today's more stringent standards for drug safety. Given the initial success of a largely empirical approach, progress in drug development in recent years has been poor and, undoubtedly there is great need for new less toxic treatments for human diseases by parasitic trypanosomes and leishmanias. In view of the economies of the Third World countries suffering most from these diseases, such drugs will have to be cheap and simple to administer.

Potential Chemotherapeutic Targets for Trypanosomiasis and Leishmaniasis
========================================================================

In this genomic, proteomic, and bioinformatics era of target identification, scores of potential targets for antitrypanosomal and antileishmanial chemotherapy will be emerging. In the pre-genomic era, basic research in molecular biology and multidimensional research initiatives has identified some biological features associated with the development of trypanosomiasis that have been well documented and studied extensively. Ergosterol biosynthesis, parasite specific proteases and reductases, purine salvage and phospholipid biosynthesis (for review see [@b96-dti-2-2007-129]) could be turned into targets, provided that the following two requirements can be met: (a) the target must be essential for the survival of the parasites, and (b) the target must be such that a counterpart in the mammalian host either does not exist or is sufficiently different to allow selective inhibition ([@b100-dti-2-2007-129]). The technological advancements related to post-target selection are also important criteria. Because the target must be suitable for study at the molecular level that include most importantly the high throughput screening for which convenient, cheap and sensitive assay methods are highly desirable.

Glycolytic pathway
------------------

As trypanosomal cells are completely energetically dependent on glycolysis it might be used to develop new trypanocidal drugs ([@b73-dti-2-2007-129]). Compertmentation of glycolytic enzymes is generally assumed to result in an enhancement of the rate of glycolysis in bloodstream trypanosomes, approximately 50-times higher than that in mammalian cells ([@b11-dti-2-2007-129]). This appears to be necessary to compensate for poor yields of energy. Trypanosomes need to replicate every 6 to 8 h in mammalian blood and Varian surface glycoproteins (VSGs) must be replaced frequently to evade a host immune response ([@b27-dti-2-2007-129]). Thus it has been suggested that inhibition of any one of the glycolytic enzymes inside the glycosomes may block glycolytic activity and kill bloodstream trypanosomes ([@b19-dti-2-2007-129]; [@b73-dti-2-2007-129]). The three dimensional (3D) structure of *T. brucei* glycosomal triosephosphate isomerase (TIM), determined at 2.4 Å resolution, was found to be very similar to that of mammalian TIM ([@b101-dti-2-2007-129]). The 3D structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase (GADPH) ([@b98-dti-2-2007-129]) could provide opportunities for designing selective inhibitors as it differs from the mammalian homolog ([@b99-dti-2-2007-129]; [@b100-dti-2-2007-129]). Bloodstream *T. b. brucei* imports glucose by facilitated diffusion and the uptake of glucose apparently represents the rate-limiting step in glycolysis. The genes encoding trypanosomal glucose transporters are tandemly arranged in a multigene family consisting of two homologous groups, trypanosome hexos transporter (THT)1 and THT2. THT1-encoded glucose transporters, preferentially expressed in a bloodstream form, have a moderate sensitivity to cytochalasin B and recognize D-fructose as substrate, thereby distinguishing them from the human erythrocyte glucose transporter. They are potential targets for antitrypanosomal chemotherapy (for review, see [@b100-dti-2-2007-129]).

DNA topoisomerases
------------------

Many of the established antiprotozoal agents are known to bind to DNA. There are two potential sites for DNA binding in members of the kinetoplastida: nuclear and kinetoplast DNA. In general, DNA binding agents would be expected to be active against protozoa, but toxicity is a major factor. It was assumed that binding to DNA leads directly to inhibition of DNA-dependent processes, but it is now generally accepted that intercalating agents induce topoisomerase II -- mediated strand breaks in DNA ([@b10-dti-2-2007-129]). Trypanosomal topoisomerase II inhibitors affect both nuclear and mitochondrial DNA and may prove to be effective and safe antitrypanosomal drugs ([@b90-dti-2-2007-129]) as they differ structurally from mammalian topoisomerase II ([@b91-dti-2-2007-129]). DNA topoisomerase I could also serve as an intracellular target, as its inhibition can cause DNA-cleavage and ultimate death of trypanosomes ([@b6-dti-2-2007-129]).

Ergosterol biosynthesis
-----------------------

Ergosterol biosynthesis is a novel metabolic pathway essential for parasitic survival lacking a counterpart in the host. Several enzymes of this pathway, e.g. squalene synthase, fernesylpyrophosphate synthase are capable of depleting endogenous sterols, and therefore represent viable chemotherapeutic targets (for review, see [@b68-dti-2-2007-129]).

Purine salvage pathway
----------------------

Some striking differences between parasites and their mammalian host are apparent in purine metabolism. Unlike their mammalian host, most parasites lack the de novo purine biosynthetic mechanisms and rely on salvage pathways to meet their purine needs. There are sufficient distinctions between enzymes of the purine salvage pathway in host and parasite that can be exploited to design specific inhibitors or "subversive substrates" for the parasitic enzymes. Furthermore, the specificities of purine transport, the first step in purine salvage, differ significantly between parasites and their mammalian host to allow selective inhibitor design (for review see [@b29-dti-2-2007-129]).

Polyamine biosynthesis
----------------------

The ability to synthesize polyamines ([Fig. 2](#f2-dti-2-2007-129){ref-type="fig"}) is vitally important for the proliferation of bloodstream HAT in an environment deficient in polyamines. As shown in [Figure 2](#f2-dti-2-2007-129){ref-type="fig"}, ornithine decarboxylase (ODC), S-adenosyl-L-methionine decarboxylase (SAMDC) and spermidine synthetase in trypanosomes serve crucial functions ([@b33-dti-2-2007-129]) and may be potential targets for antitrypanosomal chemotherapy. Little is known about trypanosomal SAMDC except that it did not cross-react with human SAMDC antiserum ([@b92-dti-2-2007-129]). Detailed comparison of mammalian and trypanosomal SAMDCs have not yet been done nor have crystal structure and amino acid sequence been determined, steps important for designing drugs active against this enzyme.

Trypanothione is a conjugate of glutathione and the polyamine spermidine. This polyamine component of the structure of trypanothione disulfide (T\[S\]~2~) rationalized the actions of several antitrypanosomal and antileishmanial drugs. For example, DFMO (5), the first new drug licensed to treat HAT for over 50 years, inhibits ODC, which catalyzes the initial step in polyamine biosynthesis ([Fig. 2](#f2-dti-2-2007-129){ref-type="fig"}), decreasing the trypanothione pool. The origin of the trypanocidal effect of DFMO has not been established ([@b35-dti-2-2007-129]).

Trypanothione reductase (TR) and the synthetic enzyme of trypanothione metabolism found in trypanosomatids exemplify unique features of the organisms. As shown in [Figure 2](#f2-dti-2-2007-129){ref-type="fig"}, trypanothione synthesis proceeds from glutathione; the similar redox potentials allow for nonenzymatic thiol-disulfide exchange reactions to occur ([@b35-dti-2-2007-129]). Considerable advances have been made in characterization and inhibitor design against TR. The key enzyme of the two-step trypanothione biosynthesis, glutathionyl spermidine synthetase, was isolated, partially sequenced and kinetically analyzed ([@b60-dti-2-2007-129]). The utilization of trypanothione for the reduction of hydroperoxides has remained a matter of debate. A trypanothione peroxide activity, presumed to substitute for the glutathione peroxide activity typical of host metabolism ([@b39-dti-2-2007-129]), was observed in crude extracts of various trypanosomatids ([@b51-dti-2-2007-129]). Consistent failures to isolate putative trypanothione peroxidases, and substantial spontaneous reaction rates between trypanothione and hydrogen peroxide, led to the conclusion that trypanothione-dependent peroxide metabolism may represent a non-enzymatic event ([@b12-dti-2-2007-129]). Recent discoveries have demonstrated ([@b75-dti-2-2007-129]) that the reduction of peroxides by trypanothione is an enzymatic process, but in contrast to previous expectations, is catalyzed by two distinct proteins in concert ([@b40-dti-2-2007-129]).

Lipoamide dehydrogenase (LipDH) is another flavoprotein dependent enzyme, which has been discussed as a target molecule for antitrypanosomal therapy. In *T. cruzi*, an organism highly susceptible to oxidative stress, LipDH participates in the redox cycling of nifurtimox, one of the most effective anti-Chagas agents ([@b62-dti-2-2007-129]).

Trypanothione Reductase as a Chemotherapeutic Target
====================================================

In the pre-genomic era investigation of mode of action of arsenical drugs and glutathione biosynthesis inhibitor, buthionine sulfoximine (BSO), gave rise to the discovery of trypanothione, unique to trypanosomes and absent from the mammalian cells ([@b34-dti-2-2007-129]). In mammals, potential redox damage meets the glutathione (GSH)-based system as a first defense, during the course of which glutathione disulfide (GSSG) is formed (Equation 1).

Regeneration of protective GSH from GSSG is catalyzed by GR. In trypanosomes and leishmanias an analogous system has evolved ([@b35-dti-2-2007-129]) insofar as the disulfide (T\[SH\]~2~) differs from GSSG by the presence of a spermidine cross-link between the two glycyl carboxyl groups (compare GSSG and T\[S\]~2~). The enzyme TR reduces T\[S\]~2~ to dithiol T\[SH\]~2~ in a manner analogous to GR ([Fig. 3](#f3-dti-2-2007-129){ref-type="fig"}). With this discovery of a fundamental metabolic difference, TR was proposed and amplified further as a target for the rational design of antitrypanosomal and antileishmanial drugs ([@b34-dti-2-2007-129]; [@b89-dti-2-2007-129]; [@b4-dti-2-2007-129]; [@b55-dti-2-2007-129]; [@b88-dti-2-2007-129]).

Unlike human hosts, trypanosomes contain TR instead of analogous enzyme GR to process their cognate substrates trypanothione and glutathione, respectively. Parasite TR does not process GSSG and host GR does not reduce T\[S\]~2~ ([@b89-dti-2-2007-129]; [@b61-dti-2-2007-129]). Selective inhibitor design is probable, due to the mutually exclusive recognition and rejection of cognate substrates between host and parasite ([@b89-dti-2-2007-129]; [@b61-dti-2-2007-129]; [@b88-dti-2-2007-129]). Efficient selective blockade of TR would be expected to compromise the redox defences of the parasites, increasing their sensitivity to redox-damage based drugs, e.g. nifurtimox. A TR inhibitor might be expected to be drug in its own right or for co-administration with a redox-active drug e.g. nifurtimox. The later case may even provide synergy, allowing use of lowered doses of the redox drug ([@b15-dti-2-2007-129]).

TR is a member of the large well-characterized protein family of FAD-dependent NADPH oxido-reductases (reviewed in [@b102-dti-2-2007-129]) and share close structural and mechanistic similarities with that of GR (summarized in [Table 2](#t2-dti-2-2007-129){ref-type="table"}). It is a dimeric protein of monomer molecular mass 52kDa, providing FAD-binding, NADPH-binding, central and interface domains. There are two identical active sites, formed by residues of the FAD, NADPH, and central domains of one monomer and the interface domain of the other ([Fig. 4](#f4-dti-2-2007-129){ref-type="fig"}).

Validating suitability of trypanothione reductase as a target
-------------------------------------------------------------

To validate TR as a viable target for rational drug design, inhibition of TR *in vitro* should correlate with an observable effect *in vivo*. This is a difficult test to satisfy unambiguously; biochemical and molecular biological attempts had been made to probe TR as a reasonable drug target. In absolute terms, disruption or deletion of the TR genes in parasites should be lethal. Over-expression of TR in transfected *L. donovani* promastigotes was not found to alter the sensitivity to hydrogen peroxide indicating that the regeneration of T\[SH\]~2~ from its disulfide after oxidative challenge is not the rate-determining feature of the defense system ([@b58-dti-2-2007-129]). Over-expression of TR in *T. cruzi* led to gene rearrangements when antisense modulation of TR expression was attempted ([@b93-dti-2-2007-129]). Disruption of two of the TR alleles of *Leishmania* failed to produce a null mutant, and actually produced a third copy of TR gene by genomic rearrangement to a larger chromosome ([@b28-dti-2-2007-129]). Down-regulation of TR using a *trans*-dominant mutation strategy demonstrated that even with only 15% residual TR activity, promastigote growth is still supported in culture ([@b94-dti-2-2007-129]). It was proposed that any rationally designed inhibitor of TR must attain \>85% inhibition for activity as an antileishmanial species, but it was pointed out that such cells are more sensitive to oxidative insult, such as the oxidative burst of macrophages, and that clinically usable TR inhibitors may need to be as effective *in vivo* ([@b94-dti-2-2007-129]). Later it had been demonstrated that TR absence is incompatible with parasite survival and validated TR as a *bonafide* drug target. As it was not possible to obtain viable *Leishmania* devoid of TR catalytic activity, specific inhibitors of this enzyme are likely to be useful antileishmanial agents for chemotherapeutic use ([@b95-dti-2-2007-129]).

Sequence alignment of TRs and human GRs (hGRs) showed that relative to TR hGR has an N-terminal extension, a C-terminal truncation and several deletion and insertions throughout the sequence. The most striking regions of homology are 14-residue sequence containing the redox-active cysteine residues and the 10-residue sequence containing the active site histidine. Although the disulfide-binding site in TR in general rather closely resembles that for GSSG in GR, they have over 1000-fold selectivity for their cognate substrates, the molecular basis for which involves size, charge and hydrophobicity of their active sites. TR binding site is much wider in the outer region (\~22 Å × 20 Å × 28 Å) due to different orientations of two helices in the FAD domains ([@b63-dti-2-2007-129]). The TR active site is more hydrophobic and has an overall negative charge to attract its positively charged and more hydrophobic polyamine containing cognate substrate trypanothione and repel the negatively charged smaller host substrate glutathione. Conversely, the GR active site is smaller and positively charged, repelling the larger and positively charged trypanothione. The X-ray crystal structures of TRs from *Crithedia fasciculata* ([@b63-dti-2-2007-129]; [@b55-dti-2-2007-129]), and *T. cruzi* have been solved ([@b64-dti-2-2007-129]; [@b103-dti-2-2007-129]). The crystal structure of TR in complex with trypanothione was solved ([@b7-dti-2-2007-129]) as was the crystal structure of TR complexed with the alternative substrate glutathionyl spermidine ([@b2-dti-2-2007-129]) and with the weak, but selective, inhibitor mepacrine ([@b57-dti-2-2007-129]). As already pointed out, a convenient screening technology is highly desirable for a suitable substrate to expedite the drug discovery process. To this end, a convenient colorimetric plate assay suitable for automated high-throughput screening has been developed by [@b49-dti-2-2007-129].

One disadvantage of selecting TR as a drug target for the development of broad-spectrum antiparasitics is that intracellular trypanothione concentrations vary from 0.3 mM in African trypanosomes to \~3.0 mM in *Leishmania spp.*, \>99% of which is in the reduced form. As soon as TR is inhibited, T\[S\]~2~ will start to accumulate due to continuing intracellular oxidant process. It is not currently known what T\[S\]~2~/T\[SH\]~2~ ratio is lethal to the parasite. It has been suggested that the design of competitive inhibitors with *K~i~*-values in nM range will be required, and the design of irreversible inhibitors may represent a better strategy for drug development ([@b37-dti-2-2007-129]).

The following section will focus on recent discoveries of different classes of TR inhibitors, which demonstrated antiparasitic activity and promise of development of newer chemotherapeutic agents.

Rational drug design based on trypanothione reductase as a target
-----------------------------------------------------------------

The homology modeling of TR ([@b4-dti-2-2007-129]) with that of hGR shed light on the structural aspects of the enzyme also in addition to its substrate-binding mode from a theoretical perspective. Studies with various alternative peptide substrates demonstrated that the spermidine moiety of trypanothione could be conveniently replaced with *N,N*-dimethylaminopropylamide (dmapa) without loss of substrate activity. Subsequently, a series of alternative γ-glutamyl-modified trypanothione substrates were synthesized. The discovery that a benzyloxy-carbonyl (Z) group represented a suitable replacement resulted in (Z.Cys.Gly.dmapa)~2~ as a convenient alternative assay substrate in which the Z group occupies a hydrophobic pocket near Phe396' of TR ([@b52-dti-2-2007-129]; [@b30-dti-2-2007-129], [@b31-dti-2-2007-129] and [@b32-dti-2-2007-129]; [@b69-dti-2-2007-129]). This pocket was since named the Z-site, approximately enclosed by Phe396', Pro398' and Leu399'. This initial advancement in structural aspects of TR active site prompted the discovery of peptide inhibitors ([@b44-dti-2-2007-129]; [@b71-dti-2-2007-129]; [@b16-dti-2-2007-129]). The first rationally designed non-peptide inhibitors are represented by the tricyclic ring structures that are competitive *versus* trypanothione ([@b4-dti-2-2007-129]). Progress has been made in discovering large classes of inhibitors of TR over recent years, which are also found to be lethal to parasites *in vitro*.

The tricyclic compounds and congeners
-------------------------------------

Molecular modeling approaches were useful in identifying tricyclic antidepressants including phenothiazines and related structures (e.g. 9, 10) and mepacrine (11) ([Fig. 5](#f5-dti-2-2007-129){ref-type="fig"}) as competitive inhibitors of TR but not GR ([@b4-dti-2-2007-129]; [@b57-dti-2-2007-129]; [@b15-dti-2-2007-129]). The tricyclic moiety of these compounds were shown to lodge against the hydrophobic wall of TR active site formed by Trp21 and Met113, with the aminopropyl side chain pointing towards the Glu466' and Glu467' residues. The synthesis and biological evaluation of a series of dibenzazepine analogs ([@b45-dti-2-2007-129]), N-acylpromazines, 2-substituted phenothiazines, and trisubstituted promazines failed to show any improvements over the parent leads ([@b15-dti-2-2007-129]).

The antimalarial drug mepacrine (11), an acridine derivative, is also a competitive inhibitor of TR. The acridine ring also aligns to the hydrophobic wall of TR formed by Trp21 and Met113, but the alkylamino side chain point towards Glu18, unlike the tricyclics described above ([@b8-dti-2-2007-129]). Sulfonamides and urea derivatives of mepacrine with varying methylene spacer lengths (e.g. 12, 13) were found to be superior inhibitors of TR relative to mepacrine with the best inhibitors being 40-fold more potent ([@b17-dti-2-2007-129]). A series of synthetic 9,9-dimethylxanthene derivatives (e.g. 14) were shown to be competitive inhibitors of TR which are comparable to known tricyclic inhibitors of TR ([@b18-dti-2-2007-129]).

It is important to note that as required in principle for an ideal drug target, inhibition of TR *in vitro* should also correlate with antiparasitic activity *in vitro* against *T. brucei, T. cruzi* and *L. donovani*. However, no strong correlation between TR-inhibitory activity and *in vitro* anti-parasitic activity was observed indicative of unfavorable pharmacokinetic profiles.

2-Aminodiphenylsulfides and its congeners
-----------------------------------------

Modification of the central ring of the phenothiazines furnished the 2-aminodiphenylsulfides, termed 'open chain chlorpromazines'. Using a microplate assay to screen TR inhibitors, this group of compounds was discovered to be potent competitive inhibitors ([Fig. 6](#f6-dti-2-2007-129){ref-type="fig"}). Compound 15 was the best inhibitor in the preliminary series ([@b38-dti-2-2007-129]). Based on these results and molecular modeling studies, a series of bis (2-aminodiphenylsulfides) were synthesized and compound 16 was shown to be the most potent in this series ([@b46-dti-2-2007-129]). Further improvement was evident with a newer generation of bis(2-aminodiphenylsulfides) (e.g. 17) corresponding to attachment of an additional hydrophobic side to an analog of compound 16. The large volume of the TR active site justified the introduction of an additional hydrophobic group to the end of the side chain ([@b47-dti-2-2007-129]).

All the compounds demonstrated antiparasitic activity *in vitro* at low micromolar ranges. However, no correlations between TR inhibition and *in vitro* antiparasitic activity were apparent.

Quaternary alkylammonium compounds
----------------------------------

The quaternization of tertiary alkylamine ω-nitrogen atom of chlorpromazine by substituted benzyl and other aromatic or heterocyclic groups resulted the discovery of quaternary alkylammonium phenothiazines as a new class of linear competitive inhibitors of TR ([Fig. 7](#f7-dti-2-2007-129){ref-type="fig"}) ([@b59-dti-2-2007-129]). The permanent positive charge on the distal nitrogen atom of the tricyclic's side chain contributed to binding was estimated as ≥5.6 kcal.mol^−1^ by comparison with the analog with cationic nitrogen atom of the quaternary (18) replaced by an ether oxygen atom (19). The major contribution to improving *K~i~* value and inhibition strength was accomplished by incorporating the hydrophobic *N*-benzyl substituents. The best inhibitor identified was compound 19, containing a 3, 4-dichlorobenzyl substituent (\~2 orders of magnitude \>chlorpromazine).

Detailed molecular modeling studies helped to establish docking orientations and energies by revealing involvement of: (i) the major hydrophobic pocket (Trp21, Met113, Tyr110), (ii) the "Z"-site (Phe396', Pro398', Leu399') and (iii) the ionic interactions possible for the quaternary cationic nitrogen with nearby side chains of Glu466' and Glu467' ([Fig. 8](#f8-dti-2-2007-129){ref-type="fig"}) ([@b1-dti-2-2007-129], [@b59-dti-2-2007-129]). This "three point attachment", a concept initially designed by [@b76-dti-2-2007-129] to explain chiral specificity of enzymes, has allowed on average a 30-fold improvement of *K~i~* values against TR ([@b59-dti-2-2007-129]).

Similarly, the quaternization of the side chain tertiary nitrogen atom of the 'open chain chlorpromazines' also showed improvements in inhibition up to 40-fold. The most potent compound synthesized from this series was the 3, 4-dichlorobenzyl analog (20) ([@b82-dti-2-2007-129]). All analogs demonstrated strong inhibition, some in lower nM ranges, against the blood stream form of *T. brucei*. Antiparasitic activity was not solely determined by the inhibition strength against TR; a strong contribution from hydrophobicity was also observed. Although active against *L. donovani*, none showed major improvement in this activity relative to their parent compounds. Some of the analogs also showed improved inhibition against the amastigote stage of *T. cruzi* with ED~50~ values \<1 μM ([@b59-dti-2-2007-129]; [@b82-dti-2-2007-129]).

Polyamine derivatives
---------------------

As shown in [Scheme 1](#f15-dti-2-2007-129){ref-type="fig"}, the natural disulfide substrate of TR, T\[S\]~2~, differs from the analogous host's GSSG only by the presence of a spermidine (a polyamine) cross-link between the two glycyl carboxyl groups. This discrimination between parasite and host substrate served as a criterion for developing polyamine derivatives as selective inhibitors of TR ([@b78-dti-2-2007-129]; [@b79-dti-2-2007-129], [@b80-dti-2-2007-129]; [@b3-dti-2-2007-129]; [@b67-dti-2-2007-129]; [@b5-dti-2-2007-129]). This approach led to the discovery of series of potent selective competitive inhibitors of TR, several selected compounds are included in [Figure 9](#f9-dti-2-2007-129){ref-type="fig"} (compounds 21, 22).

Solid phase synthesis approaches allowed for the expedient synthesis of polyamine-based focused libraries as potential TR inhibitors. Several potent inhibitors were identified with low nM activity ([@b77-dti-2-2007-129]; [@b22-dti-2-2007-129]).

Most of these compounds also displayed potent *in vitro* antiparasitic activity against *T. brucei* with ED~50~ values \<1 μM ([@b80-dti-2-2007-129]; [@b67-dti-2-2007-129]; [@b5-dti-2-2007-129]). These preliminary antiparasitic activity *in vitro* are suggestive of their TR involvement although well correlation between TR-inhibition and trypanocidal activity were not evident.

Bisbenzylisoquinoline alkaloids
-------------------------------

The bisbenzylisoquinoline alkaloids were also shown to be potent inhibitors of TR and trypanocidal agents ([@b41-dti-2-2007-129], [@b42-dti-2-2007-129]). Six of the alkaloids evaluated displayed potent trypanocidal activity *in vitro* against *T. cruzi* with ED~50~ values \<100 μM. The best TR inhibitor, cepharanthine (23), had an *I~50~* value of 15 μM which is the same order of magnitude as its ED~50~ against the parasites, suggesting that inhibition of TR could be the mechanism of their trypanocidal activities.

Natural products
----------------

Natural products may be considered as "nature's medicine chest" and have served as a potential source of TR-inhibitors. The natural antihypertensive agent, kukoamine A (24), a bis (trihydro-cinnamoyl) spermidine derivative, first isolated from *Lycium chinense*, was identified as a mixed type of inhibitor of TR ([@b83-dti-2-2007-129]).

Virtual screening of a large number of chemical databases, using the TR active site as the targeted template, identified the natural spermine-based macrocyclic alkaloid lunarin (25) (originally isolated from *Lunaria biennis*) as TR-inhibitor, which was shown to inhibit the enzyme in a time-dependent manner ([@b7-dti-2-2007-129]). Further investigation with synthetic derivatives confirmed the importance of the unique structure of the tricyclic core as a motif for inhibitor design and revealed that the non-natural enantiomer may be a more suitable scaffold upon which thiophilic groups may be presented ([@b50-dti-2-2007-129]). Ajoen (26) a garlic derived natural sulfur-containing compound was established as an irreversible inhibitor and subversive substrate of both TR and GR ([@b43-dti-2-2007-129]). Most of these natural products also inhibited the parasites *in vitro* in one way or another.

Irreversible inhibitors
-----------------------

The anticancer nitrosourea drug carmustin was the first ligand to display irreversible inactivation of TR, but non-specifically as also inactivated hGR, by carbamoylating an active site cystinyl residue, which becomes accessible after being reduced by NADPH ([@b88-dti-2-2007-129]). Ajoen (26), as previously mentioned as a natural product inhibitor, is an irreversible non-specific inhibitor of TR ([@b43-dti-2-2007-129]). The first rationally designed and selective irreversible inhibitors of TR include the Pt-complexes of terpyridine derivatives (e.g. 27), which inhibit the reduced TR, presumably through occupying the Cys52 by replacing its fourth pyridine ligand ([@b9-dti-2-2007-129]). Coupling the irreversible ligand (terpyridine)Pt^2+^ complex with an 9-aminoacridine derivative (a competitive inhibitor) furnished mixed-type inhibitors (e.g. 28) ([@b56-dti-2-2007-129]). An important advancement was made with the quinacrine mustard (29), which was shown to selectively and irreversibly inactivate TR in a time-dependent manner with a stoichiometry of two inhibitors bound per monomer. The rate of inactivation was dependent upon the oxidative states of TR, with NADPH-reduced TR form being inactivated faster. The structure of TR-quinacrine mustard-adduct solved to 2.7Å revealed that two molecules of ligand are bound in the trypanothione binding site of TR. Each acridine moiety interacts through π-stacking, while only one of the acridine groups interacts with a trypanothione residue in a similar fashion ([@b87-dti-2-2007-129]).

Recently, several Mannic bases (e.g. 30) were shown by [@b66-dti-2-2007-129] to be irreversible inhibitors of TR. HPLC, NMR and MS analyses were performed to delineate their mechanism of action and found that divinyl ketone are the key intermediates to irreversibly inhibit TR. ESI- and MALDI-TOF-MS of TR, modified by Mannic base or corresponding divinyl ketone, demonstrated specific alkylation of Cys52 in a manner as shown in [Figure 13](#f13-dti-2-2007-129){ref-type="fig"} ([@b66-dti-2-2007-129]).

Sixteen novel Pd-complexes of the bioactive nitrofuryl thiosemicarbazones were synthesized and tested for their *in vitro* activity ([@b81-dti-2-2007-129]). Most complexes showed higher *in vitro* trypanocidal activity against *T. cruzi* than the standard drug nifurtimox. Overall, the activities of Pd complexes ≥ their parent compounds. It has been suggested that main trypanocidal mechanism was the production of oxidative stress as a result of their bioreduction with the reductive enzymes, although strong DNA-adduct formation was also evident ([@b81-dti-2-2007-129]).

Subversive substrates of trypanothione reductase
------------------------------------------------

Nifurtimox (6) and related compounds exert their parasiticidal activity through acting as futile, superoxide ion producing substrates of TR. TR and GR reduce these futile, superoxide ion producing substrates in a single electron step (NADPH + 2RNO~2~ → 2RNO~2~^•−^ + 2H^+^; 2RNO~2~^•−^ + O~2~ → 2RNO~2~ + O~2~^•−^), a process by which NADPH and O~2~ are wasted and T\[SH\]~2~ is inhibited/oxidized by scores of newly formed superoxide ions causing a reduction in thiol/disulfide titer and thus producing oxidative stress ([@b53-dti-2-2007-129]; [@b88-dti-2-2007-129]). This group of compounds, known as 'subversive substrates' or 'turncoat inhibitors', are best represented by nitrofurans or quinones, chemically modified to take into account the substrate specificity for TR over GR ([@b13-dti-2-2007-129] and [@b14-dti-2-2007-129]). Thus, chinifur (31), a nitrofuran derivative with a positively charged side chain, was discovered as a selective inhibitor and subversive substrate of TR ([@b13-dti-2-2007-129]). Recently, the anti-TR activities of a series of nitrofuran and nitroimidazole derivatives were studied to examine the mechanism of action of different types of nitro-group containing compounds. The results indicated that the nitrofurans, e.g. nifurtimox act as futile-cyclers as discussed above, whereas 5-nitroimidazoles, e.g. megazole (32) act as thiol scavengers particularly for T\[SH\]~2~ thus reducing the thiol/disulfide titer which is detrimental for the parasites' survival ([@b70-dti-2-2007-129]). [@b97-dti-2-2007-129] explored three possible binding sites of TR and GR, i.e. the active site, the dimer interface and the NADPH binding site to study the mechanism of action of nitrofuran and nitrothiophene analogs. It has been suggested that this class of compounds act as either uncompetitive or mixed inhibitors of TR. Moreover, it has also been indicated that the presence of an α-helix connecting the active site of TR with the interface may be crucial for charge-transfer processes.

1,4-naphthaqiuinone derivatives (e.g. 33) are examples of quinine-based subversive substrates of TR, designed after plumbagin. Compound 33 proved to be a potent subversive substrate and an effective uncompetitive inhibitor of TR *versus* T\[SH\]~2~ and NADPH ([@b86-dti-2-2007-129]).

Most of these compounds were potent inhibitors of the parasites *in vitro*. For a series of naphthaquinones, a correlation between their potency as subversive substrates *in vitro* and trypanocidal activity *in vivo* has been demonstrated ([@b86-dti-2-2007-129]). This 'alternative approach to chemotherapy of Chagas disease' has been considered one of the most promising advances.

Chemotherapeutic Prospects of the Trypanothione Reductase Inhibitors
====================================================================

For an enzyme inhibitor to become a practical drug, several criteria must be met: (i) the biochemical pathway that is inhibited must be related to the disease state in such a way that inhibition of that pathway in a patient is therapeutic; (ii) the enzyme inhibitor must be specific so that unwanted inhibition of other pathways or receptors does not occur at therapeutic doses; (iii) the compounds must have the pharmacokinetic characteristics of a practical drug, i.e. must be absorbed, must penetrate to the site of action and must have a reasonably predictable dose-response relationship and duration of action; (iv) the compound must have an acceptable toxicological profile in animals, and the results of clinical studies in humans must demonstrate an appropriate balance between benefits and risks in therapeutic use; (v) the compound must survive a long and expensive clinical development process and ultimately be approved by regulatory agencies; (vi) the compound must be economically viable in the marketplace and compete successfully with other therapeutic alternatives ([@b21-dti-2-2007-129]). The criteria (i) and (ii) have already been addressed while selecting the target, and thus, all of the above mentioned inhibitors have fulfilled them. Pharmacological and toxicological studies in animal models are needed to meet other criteria.

Although many potent inhibitors of TR have been discovered through enzyme screening, *in vivo* evaluation of these lead compounds are scant. Several polyamine derivatives that were shown to be potent trypanocidals *in vitro* (with ED~50~ values in submicromolar ranges) failed to prolong the lives of experimental mice infected with trypanosomes or to cause a significant decrease in bloodstream parasitemia of infected mice ([@b80-dti-2-2007-129]). However, none of the compounds exerted overt toxicity in mice. It has been suggested that the lack of *in vivo* trypanocidal activity may be due to their rapid elimination and/or metabolism. Since these compounds are reversible inhibitors of TR, concentrations of these compounds may not be maintained, and as a result, TR activity will not be significantly decreased ([@b80-dti-2-2007-129]). It has also been suggested that converting reversible inhibitors into irreversible inhibitors through complexation with metal ions might be a reasonable strategy for identifying improved leads with enhanced *in vivo* profiles. Clomipramine and thioridazine were shown to be effective in treatment of mice with experimental Chagas disease ([@b84-dti-2-2007-129], [@b85-dti-2-2007-129]). The investigation of effects of clomipramine on *T. cruzi* infected mice demonstrated that clomipramine at 5 mg/kg daily doses for 30 days, or two doses of clomipramine 40 mg/kg given intraperitoneally at 1h and 7 days after infection, was not toxic for the host, but was effective against the parasite. Parasitamiasis became negative and only mild heart structural and elecctrocardiographic alterations were detected in chronic phase in the group treated with clomipramine 5 mg/kg. In mice treated with 40 mg/kg, none of these alterations was detected ([@b84-dti-2-2007-129]). Overall, it has been shown that clomipramine and thioridazine significantly modified the natural evolution of the infection. Cardiac function and survival of infected and treated animals were not different from noninfected animals. Thioridazine or clomipramine are currently registered as drugs (antipsychotics) and meet all the above mentioned criteria. However, to consider them as antitrypanosomal drugs, dose becomes an important obstacle, since they need to be active at a dose which is known to be tolerated by psychiatric patients without causing adverse events. Apart from their potent *in vitro* activity and a preliminary report of *in vivo* activity, more detail studies are needed to establish their efficacy and safety and also to improve their antiparasitic potency. Overall, it would not be overenthusiastic to consider phenothiazines and related tricyclic antidepressants and the other inhibitors of TR as important drug leads for development of future chemotherapy against trypanosomal and leishmanial infections.

Conclusion
==========

The demand for chemotherapeutic agents for the treatment of Chagas disease, sleeping sickness and kala azar is desperate. An account of the different possible targets for rational drug design with special emphasis on trypanothione reductase has been focused. TR has been established as a potential target in several studies although it is not universally accepted. The literature, molecular graphics and other medicinal chemistry approaches have led to the development of a large class of compounds as inhibitors of TR and the parasites. Considerable progress have been made in terms of identification, validation and inhibitor design based on trypanothione reductase as a target, which will be milestones towards the goal of developing chemotherapy against these devastating diseases. This review has revealed several approaches based on TR towards the development of new drugs against the parasitic diseases. Reasonable activity against parasites living in both culture and in mouse macrophases has been demonstrated by most classes of compounds, full activity against whole animal model to be achieved. It has been suggested that the alternative approaches like subversive substrates and metal bound inhibitors would be advantageous in achieving reasonable *in vivo* activity against the parasite infection. Only the phenothiazines and related tricyclic antidepressants were shown to reduce parasite burden in infected mice. Development of the quaternary alkylammonium chlorpromazines and congeners, with an additional hydrophobic moiety provided, on an average, up to about 30-fold more potent inhibitors of TR. The charge on N^+^ is needed for interaction at the Glu466' or Glu467' of the enzyme active site, the tricyclic or equivalent moiety interacts with the major hydrophobic cleft and the second hydrophobic moiety may interact with Z-site. Studies with other classes of inhibitors, in addition to the TR:inhibitor complex's X-ray crystal structure, provided similar TR:inhibitor interactive motifs. As with any rational drug design case at the current stage of computational development, the problem of bioavailability, pharmacokinetic, metabolism and targeting have not been addressed. The prodrug approach might be a reasonable step in correcting some of the aforementioned problems in developing TR inhibitors with observable effects *in vivo* and might open a new path towards the development of drugs against these parasitic diseases.

The author wish to gratefully acknowledge Professors K. T. Douglas of Manchester, A. H. Fairlamb of Dundee and R. L. Krauth-Siegel of Heidelberg and others who are pioneering the research in the endeavor of trypanothione reductase and many of their research have been cited in this review.
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![Metabolism and function of trypanothione, showing possible sites of action of trypanocidal compounds. The insert above illustrates the futile redox cycling by nitro compounds (RNO~2~) to form hydrogen peroxide (H~2~O~2~) and hydroxyl radicals (OH^•^). Abbreviations: BSO, buthionine sulfoximine; DFMO, difluoromethylornithine; R-As=O, melarsen oxide; Mel T, melarsen trypanothione adduct; PUT, putrescine; SPD, spermidine; dSAM, decarboxylated S-adenosylmethionine; MTA, methylthioadenosine (modified from [@b61-dti-2-2007-129]).](dti-2-2007-129f2){#f2-dti-2-2007-129}
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![Structure of trypanothione reductase with FAD, NADPH and trypanothione bound (modified from [@b7-dti-2-2007-129]).](dti-2-2007-129f4){#f4-dti-2-2007-129}
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![Compound **18** docked into active site of TR to show major interactions (taken from [@b1-dti-2-2007-129]).](dti-2-2007-129f8){#f8-dti-2-2007-129}
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![Proposed reaction mechanisms for the modification of protein thiol (RSH), e.g. Cys52 in *T. cruzi* trypanothione reductase by an unsaturated Mannic base such as **30** (Modified from [@b66-dti-2-2007-129]).](dti-2-2007-129f13){#f13-dti-2-2007-129}
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###### 

The major trypanosomiasis and leishmaniasis, causative agents, their global burdens in terms of Disability Adjusted Life Years (DALY) and current treatments.

  Disease                                        Causative agents                                       DALY[\*](#tfn1-dti-2-2007-129){ref-type="table-fn"} (million/year)   Current Treatments
  ---------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------- -------------------------------------------
  African trypanosomiasis or sleeping sickness   *Trypanosoma brucei gambiense and T. b. rhodesiense*   1.2                                                                  Suramine, pentamidine, DFMO, tryparsamide
  American trypanosomiasis or Chagas disease     *T. cruzi*                                             0.6                                                                  Benznidazole, nifurtimox
  Visceral leishmaniasis or kalazar              *Leishmania donovani*                                  1.7                                                                  Pentostam, glucantime,
  Dermal leishmaniasis or tropical sore          *L. major, L. tropica, L. braziliensis, L. mexicana*                                                                        aminosidine

Taken from World Health Report 1999, publ. *World Health Organization Geneva* (1999).

###### 

Properties of trypanothione reductase and glutathione reductase; taken from literature ([@b102-dti-2-2007-129]).

  Property                         Trypanothione reductase   Glutathione reductase                                             
  -------------------------------- ------------------------- ----------------------- ------------- ------------- ------------- -------------
  Flavin                           FAD                       n.d.                    FAD           FAD           FAD           FAD
  Pyridine dinucleotide            NADPH                     NADPH                   NADPH         NADPH         NADPH         NADPH
  Subunit M~r~ (Da)                54000                     52940                   53900         53400         48700         52500
  Amino acids/subunit              491                       491                     492           492           450           478
  Oligomeric structure             dimer                     dimer                   dimer         dimer         dimer         dimer
  E~ox~, λ~max~ (nm)               464                       463                     461           464           462           460
  ɛ~0~ at λ~max~ (mM^−1^cm^−1^)    11.3                      11.5                    11.2          10.6          \-            11.3
  charge transfer in EH~2~         yes                       yes                     yes           yes           yes           yes
  ɛ~0~ at λ~530~ (mM^−1^cm^−1^)    3.63                      4.2                     4.9           3.7           \-            4.5
  K~m~ (μM) trypanothione          53 (51, 58)               36                      45 (55, 50)   31 (18)       2000          
  Glutathione                      \-                        \-                      \-            \-            66 (61, 70)   65
  k~cat~ (min^−1^) trypanothione   31000 (286000)            10760                   14299         9600          6100          9.6
  glutathione                      3.1                       \<2                     \-            \-            44000         12600
  k~cat~/K~m~ (M^−1^sec^−1^)       9.8 × 10^6^               5.0 × 10^6^             5.3 × 10^6^   5.2 × 10^6^   6.2 × 10^6^   3.1 × 10^6^
  K~m~^app^ (NADPH)                7                         9                       5             5             16 (25)       9
